Gossamer in Agreement with Merck for Solid Tumor Studies
12 November 2019 - 11:56PM
Dow Jones News
By Michael Dabaie
Gossamer Bio Inc. (GOSS) said it is in a clinical collaboration
agreement with Merck & Co. Inc. (MRK) to evaluate the
combination of Gossamer's investigational candidate GB1275 and
Merck's Keytruda in patients with advanced solid tumors.
Gossamer will conduct a Phase 1/2 study, Keynote-A36, in
advanced solid tumors, with the Phase 1 consisting of dose
escalation of three GB1275 regimens including one with Keytruda.
The Phase 2 consists of expansion cohorts evaluating GB1275 in
combination with Keytruda or chemotherapy.
The KEYNOTE-A36 Phase 1/2 trial is underway, enrolling patients
in the U.S. and U.K. to treat solid tumor types, including
pancreatic, gastric, esophageal, colorectal, prostate and triple
negative breast.
Gossamer said it expects to report initial data from the Phase 1
portion of the study in the second half of 2020.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 12, 2019 07:41 ET (12:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024